These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18592985)

  • 1. [Guide to the treatment and care of lymphangioleiomyomatosis].
    Hayashida M
    Nihon Kokyuki Gakkai Zasshi; 2008 Jun; 46(6):428-31. PubMed ID: 18592985
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-acting depot of LH-RH agonist].
    Akaza H
    Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lymphangioleiomyomatosis].
    Cottin V; Archer F; Khouatra C; Lazor R; Cordier JF
    Presse Med; 2010 Jan; 39(1):116-25. PubMed ID: 19944562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 6. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary lymphangioleiomyomatosis: presentation and results of treatment].
    Korzeniewska-Koseła M; Maziarka D; Wesołowski S; Langfort R; Słodkowska J; Bestry I; Kowalski J; Kuś J
    Pneumonol Alergol Pol; 2001; 69(11-12):626-34. PubMed ID: 12134438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
    Koga H; Naito S
    Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
    [No Abstract]   [Full Text] [Related]  

  • 10. Pulmonary lymphangiomyomatosis (LAM) developing chylothorax.
    Morimoto N; Hirasaki S; Kamei T; Horiike A; Miyatake H; Ogita Y; Nakano H
    Intern Med; 2000 Sep; 39(9):738-41. PubMed ID: 10969906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleural disease in lymphangioleiomyomatosis.
    Almoosa KF; McCormack FX; Sahn SA
    Clin Chest Med; 2006 Jun; 27(2):355-68. PubMed ID: 16716823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Meinhardt W; Horenblas S
    J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent chylothorax in lymphangioleiomyomatosis treated by intrapleural instillation of povidone.
    Rizzardi G; Loy M; Marulli G; Rea F
    Eur J Cardiothorac Surg; 2008 Jul; 34(1):214-5. PubMed ID: 18455413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Dearnaley DP; Norman AR; Shahidi M
    J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary lymphangioleiomyomatosis: literature update.
    Valentín-Mendoza S; Nieves-Nieves J; Fernández-Medero R; Fernández-Gonzales R; Adorno-Fontánez J; Adorno-Fontánez E
    Bol Asoc Med P R; 2013; 105(3):64-9. PubMed ID: 24282925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leuprorelin acetate depot].
    Mashimo T
    Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
    [No Abstract]   [Full Text] [Related]  

  • 17. [Endocrine therapy for prostate cancer in the future].
    Usami M
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary lymphangioleiomyomatosis: a rare presentation.
    Bhat MA; Bhat GM
    Indian J Chest Dis Allied Sci; 2004; 46(3):209-11. PubMed ID: 15553210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
    Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
    Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chylothorax in an 87-year-old patient].
    Richter MJ; Baumgartner R; Leuchte HH
    Internist (Berl); 2013 Jan; 54(1):105-9. PubMed ID: 23111591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.